Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

I1656

Sigma-Aldrich

Idarubicin hydrochloride

solid

Synonyme(s) :

(7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione, 4-Demethoxydaunorubicin hydrochloride, DMDR, IMI-30, Idamycin

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C26H27NO9 · HCl
Numéro CAS:
57852-57-0
Poids moléculaire :
533.95
Numéro CE :
260-990-7
Numéro MDL:
MFCD00866457
Code UNSPSC :
12352200
ID de substance PubChem :
24278488
Nomenclature NACRES :
NA.77

Forme

solid

Niveau de qualité

200

Auteur

Johnson & Johnson

Conditions d'expédition

wet ice

Température de stockage

2-8°C

Chaîne SMILES 

[H][C@@]1(C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O)O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5

InChI

1S/C26H27NO9/c1-10-21(29)15(27)7-17(35-10)36-16-9-26(34,11(2)28)8-14-18(16)25(33)20-19(24(14)32)22(30)12-5-3-4-6-13(12)23(20)31/h3-6,10,15-17,21,29,32-34H,7-9,27H2,1-2H3/t10-,15-,16-,17-,21+,26-/m0/s1

Clé InChI

XDXDZDZNSLXDNA-TZNDIEGXSA-N

Informations sur le gène

human ... TOP2A(7153)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Application

Idarubicin is an anthracycline antibiotic that is an anti-leukemia agent with higher DNA binding capacity and greater cytotoxicity than daunorubicin.

Actions biochimiques/physiologiques

Topoisomerase II inhibitor

Caractéristiques et avantages

This compound is a featured product for Apoptosis research. Click here to discover more featured Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictogrammes

Skull and crossbonesHealth hazard
GHS06,GHS08

Mention d'avertissement

Danger

Mentions de danger

H300,H351,H360

Conseils de prudence

P201 - P301 + P310 + P330

Classification des risques

Acute Tox. 2 Oral - Carc. 2 - Repr. 1B

Code de la classe de stockage

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Équipement de protection individuelle

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 6

1 of 6

Ifosfamide ≥98%

Sigma-Aldrich

I4909

Ifosfamide

2-Fluoroadenine-9-β-D-arabinofuranoside DNA synthesis and methylation inhibitor

Sigma-Aldrich

F2773

2-Fluoroadenine-9-β-D-arabinofuranoside

Clofarabine ≥98% (HPLC)

Sigma-Aldrich

C7495

Clofarabine

Teniposide ≥97% (HPLC)

Sigma-Aldrich

SML0609

Teniposide

Mitoxantrone hydrochloride European Pharmacopoeia (EP) Reference Standard

M2305000

Mitoxantrone hydrochloride

Cytarabine European Pharmacopoeia (EP) Reference Standard

C3350000

Cytarabine

Jungwon Huh et al.
American journal of hematology, 87(10), 961-968 (2012-08-14)
Core binding factor (CBF) AML with the D816 C-KIT gene mutation demonstrate inferior treatment outcomes. However, the remaining cases without the D816 C-KIT mutation imply a requirement of more sophisticated dissection of the patients according to their prognosis. In this
Malgorzata Tokarska-Schlattner et al.
Molecular pharmacology, 61(3), 516-523 (2002-02-21)
Anthracyclines are among the most efficient drugs of cancer chemotherapy, but their use is limited by a significant risk of cardiotoxicity, which is still far from being understood. This study investigates whether impairment of mitochondrial creatine kinase (MtCK), a key
Claude Gardin et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(3), 321-327 (2012-12-19)
Although standard chemotherapy remains associated with a poor outcome in older patients with acute myeloid leukemia (AML), it is unclear which patients can survive long enough to be considered as cured. This study aimed to identify factors influencing the long-term
D Reinhardt et al.
Klinische Padiatrie, 224(6), 372-376 (2012-07-24)
The survival rate of children and adolescents suffering acute myeloid leukemia (AML) has been significantly improved within the last decades. This has been achieved by a continuously intensified therapy and progress in supportive care to prevent and treat complications. In
Monica L Guzman et al.
Proceedings of the National Academy of Sciences of the United States of America, 99(25), 16220-16225 (2002-11-27)
Acute myelogenous leukemia (AML) is typically a disease of stem progenitor cell origin. Interestingly, the leukemic stem cell (LSC) shares many characteristics with normal hematopoietic stem cells (HSCs) including the ability to self-renew and a predominantly G(0) cell-cycle status. Thus
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique